Literature DB >> 9417056

Overexpression of cholesterol 7alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. LDL transport and plasma LDL concentrations are reduced.

D K Spady1, J A Cuthbert, M N Willard, R S Meidell.   

Abstract

This study was undertaken to determine the effect of transient overexpression of hepatic cholesterol 7alpha-hydroxylase on low density lipoprotein (LDL) cholesterol transport in mice lacking LDL receptors (LDL receptor-/-). Primary overexpression of hepatic 7alpha-hydroxylase in LDL receptor-/- mice was accompanied by a dose-dependent decrease in the rate of LDL cholesterol appearance in plasma (whole body LDL cholesterol transport) and a corresponding reduction in circulating LDL cholesterol levels. The increase in hepatic 7alpha-hydroxylase activity necessary to achieve a 50% reduction in plasma LDL cholesterol concentrations was approximately 10-fold. In comparison, cholestyramine increased hepatic 7alpha-hydroxylase activity approximately 3-fold and reduced plasma LDL cholesterol concentrations by 17%. This study demonstrates that augmentation of hepatic 7alpha-hydroxylase expression is an effective strategy for lowering plasma LDL concentrations even in animals with a genetic absence of LDL receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9417056     DOI: 10.1074/jbc.273.1.126

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

1.  The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.

Authors:  Jian Shen; Donna K Arnett; Laurence D Parnell; Chao-Qiang Lai; Robert J Straka; Paul N Hopkins; Ping An; Mary F Feitosa; José M Ordovás
Journal:  J Cardiovasc Pharmacol       Date:  2012-03       Impact factor: 3.105

2.  Dietary fatty acids regulate cholesterol induction of liver CYP7alpha1 expression and bile acid production.

Authors:  Yan Li; Meng Jun Hou; Jing Ma; Zhi Hong Tang; Hui Lian Zhu; Wen Hua Ling
Journal:  Lipids       Date:  2005-05       Impact factor: 1.880

Review 3.  Recent advances in liver-directed gene therapy for dyslipidemia.

Authors:  Kazuhiro Oka; Lawrence Chan
Journal:  Curr Atheroscler Rep       Date:  2002-05       Impact factor: 5.113

4.  Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.

Authors:  Ira J Goldberg; Li-Shin Huang; Lesley A Huggins; Shuiqing Yu; Prabhakara R Nagareddy; Thomas S Scanlan; Joel R Ehrenkranz
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

5.  Thyroid hormone receptor agonists reduce serum cholesterol independent of the LDL receptor.

Authors:  Jean Z Lin; Alexandro J Martagón; Willa A Hsueh; John D Baxter; Jan-Åke Gustafsson; Paul Webb; Kevin J Phillips
Journal:  Endocrinology       Date:  2012-10-19       Impact factor: 4.736

6.  Cholesterol lowering in low density lipoprotein receptor knockout mice overexpressing apolipoprotein E.

Authors:  J Osuga; M Yonemoto; N Yamada; H Shimano; H Yagyu; K Ohashi; K Harada; T Kamei; Y Yazaki; S Ishibashi
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

7.  A bovine papillomavirus-1 based vector restores the function of the low-density lipoprotein receptor in the receptor-deficient CHO-ldlA7 cell line.

Authors:  Jaana Tammur; Hiljar Sibul; Ene Ustav; Mart Ustav; Andres Metspalu
Journal:  BMC Mol Biol       Date:  2002-04-19       Impact factor: 2.946

8.  Identification of a novel hypocholesterolemic protein, major royal jelly protein 1, derived from royal jelly.

Authors:  Yuri Kashima; Satoshi Kanematsu; Saori Asai; Mio Kusada; Suzuyo Watanabe; Takuji Kawashima; Tadashi Nakamura; Masaya Shimada; Tsuyoshi Goto; Satoshi Nagaoka
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

9.  The liver-selective thyromimetic T-0681 influences reverse cholesterol transport and atherosclerosis development in mice.

Authors:  Ivan Tancevski; Egon Demetz; Philipp Eller; Kristina Duwensee; Julia Hoefer; Christiane Heim; Ursula Stanzl; Andreas Wehinger; Kristina Auer; Regina Karer; Julia Huber; Wilfried Schgoer; Miranda Van Eck; Jonathan Vanhoutte; Catherine Fievet; Frans Stellaard; Mats Rudling; Josef R Patsch; Andreas Ritsch
Journal:  PLoS One       Date:  2010-01-15       Impact factor: 3.240

Review 10.  FXR an emerging therapeutic target for the treatment of atherosclerosis.

Authors:  Andrea Mencarelli; Stefano Fiorucci
Journal:  J Cell Mol Med       Date:  2010-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.